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Abstract
Objective: Objective of the present analytical research work was to develop and validate Reverse Phase High  
Performance  Liquid  Chromatographic  method (RP-HPLC  Method)  for  the  Etoricoxib  in  bulk  and  tablets 
dosage form.
Methods: A RP-HPLC method has been developed and validated for estimation of ETOR in pharmaceutical 
oral dosage form.
Method A (RP-HPLC Method):  The RP-HPLC Method  for  Etoricoxib  was  developed  using  Shimadzu 
HPLC,  LC-10,  temperature  maintained  25  0C,  phenorex  Gemini  C18  (250  mm  ×  4.60  mm ×  5μm),  as 
stationary  particle,  isocratic  mode.  Water:  ACN:  OPA:  TEA  (40:60:0.1:0.1,  v/vv/v).  Mobile  phase  was 
maintained at a flow rate of 1.0 ml/min and detection was carried out at 245 nm.
Results: Etoricoxib was found to be linear in the concentration range of 8 - 12 μg/ml for RP-HPLC method. 
Retention time was found to be 2.7 min for Etoricoxib. The amount of Etoricoxib in marketed formulation was 
found to be 99.33 %.
Interpretation and Conclusion: Results of assay and validation study were found to be satisfactory. So, the 
method can be successfully applied for the routine analysis of Etoricoxib.
Keywords: Etoricoxib, RP-HPLC, ICH Guidelines
1. Introduction
Arthritis  (from Greek  arthro-,  joint  +  -itis, 
inflammation;  plural:  arthritides)  is  a  form of  joint 
disorder  that  involves inflammation of one or more 
joints. The pain from arthritis is due to inflammation 
that occurs around the joint, damage to the joint from 
disease,  daily wear and tear  of joint, muscle strains 
caused  by  forceful  movements  against  stiff  painful 
joints  and  fatigue. Arthritis  is  very  common  and 
occurs in 30% to 50% of the general population. 10% 
of  the  population  may  suffer  from  chronic  (long-
standing) arthritis. Arthritis affects people of all ages, 
rarely  in  children,  although  it  is  more  common  in 
adults  and  its  frequency  increases  with  age.  In 
general,  women  are  affected  more  frequently  than 
men. 
Etoricoxib  is  a  COX-2  selective  inhibitor. 
Cyclooxygenase (COX), also known as prostaglandin 
endoperoxide  synthase,  is  the  key  enzyme required 
for  the  conversion  of  arachidonic  acid  to 
prostaglandins.  Two  COX  isoforms  have  been 
identified, COX-1 and COX-2. In many situations, the 
COX-1  enzyme  is  produced  constitutively  (e.g.,  in 
gastric mucosa), whereas COX-2 is highly inducible 
(e.g., at sites of inflammation and cancer). Traditional 
nonsteroidal  anti-inflammatory  drugs  (NSAIDs) 
inhibit  both  enzymes,  and  a  new  class  of  COX-2 
selective  inhibitors  (COXIBs)  preferentially  inhibit 
the COX-2 enzyme.
Literature  survey  reveals  that  only  a  few 
analytical methods are reported for the estimation of 
Etoricoxib by RP-HPLC.  In  this  study efforts  were 
made to develop simple,  easy and economic HPLC 
methods  for  the  estimation  of  Etoricoxib.  The 
developed method was optimized and validated as per 
the  guidelines  of  International  conference  on 
Hormonization  (ICH)  and  demonstrated  excellent 
specificity,  linearity,  precision  and  accuracy  for 
Etoricoxib.  Validation  is  a  process  of  establishing 
documented evidence, which provides a high degree 
of assurance that a specific activity will consistently 
produce  a  desired  result  or  product  meeting  its 
predetermined  specifications  and  quality 
characteristics.  Method  validation  is  the  process  of 
demonstrating that analytical procedures are suitable 
for  their  intended  use  and  that  they  support  the 
identity,  quality,  purity,  and  potency  of  the  drug 
substances and drug products. (1, 2, 3, 4)
2. Materials and methods
2.1 Preliminary analysis of drug: Etoricoxib (ETOR) 
is  official  in  British  Pharmacopoeia  (BP).  It  is  in 
Authorized  British  Approved  Names  2002,  in 
Supplement  No.  3  Hence,  Preliminary  analysis  of 
ETOR was performed according to BP.
2.1.1 Description:  The  sample  of  ETOR  was 
observed for its color and texture.
2.1.2 Solubility:  The sample of ETOR was taken in 
test  tubes  and  observed  for  solubility  in  various 
solvents  like  DMF,  DMSO,  diluted  mineral  acids 
water, alcohol, ethanol and water. 
2.1.3  Water  Determination:  Water  content  can  be 
determined  using  Karl  Fischer  Titrimeter.  Karl 
Fischer reagent is standardized with sodium tartrate, 
then it  is titrated with the known amount of sample 
i.e.  ETOR  and  then  once  the  color  change  is 
observed, it will indicate the end point of the titration 
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and  this  in  turn  will  give  the  amount  of  moisture 
present in the sample. 
Moisture/water  content  can  be  determine  using 
following formula,
Water content = 
(Limit: Not more than 0.5 %)
2.2 Chemicals and Reagents (HPLC):  Analytically 
pure samples of Etoricoxib were kindly supplied by 
Sun  Pharmaceuticals  Ltd,  Vapi,  Gujarat, India. 
Arcoxia-60mg  (Marketed  Formulation),  Water 
(HPLC  Grade),  ACN  (HPLC Grade),  OPA,  TEA 
Themis  laboratories  Pvt.Ltd  (Mumbai,India), were 
used for the method development.
2.2 Instrument  Used:  Electronic Weighing Balance 
(Tapson’s  Analytical  Balance),  Ultrasonicator 
(Tapson’s TP-101), Cellulose Acetate Filter, 0.45 μm 
(Nylon 66), HPLC System (Shimadzu)
2.3 Selection  of  Mobile  Phase:  The  selection  was 
made on the basis of literature survey. After assessing 
the solubility of drug in different solvents as well on 
the basis of literature survey,  water  and acetonitrile 
were selected as a first choice. OPA (0.1%) and TEA 
(0.1%)  was  added  to  avoid  the  degradation  of  the 
etoricoxib.
2.4 Selection of column (stationary phase):  To get 
well  resolved,  symmetric  peak  with  highest  no. of 
theoretical plates, the solution of ETOR was analyzed 
using  different  column  as  a  stationary  phase  like 
Phenyl, C18, Amino column.
2.5 Selection  of  Analytical  Wavelength:  To 
investigate  the  appropriate  wavelength  for 
determination of ETOR, the solution of the same in 
the  mobile  phase  were  scanned  separately  by UV–
Visible spectrophotometer in the range of 200-400 nm 
and the spectrum was recorded. 
2.6 Preparation of Mobile Phase
Mobile Phase A: HPLC grade water.
Mobile  Phase  B:  Acetonotrile  was  degassed  in 
sonicator for 15 min.
2.7  Preparation  of  Standard  Stock  Solution:  
Standard  stock solution was prepared  by dissolving 
10  mg  of  ETOR  in  100  ml  mobile  phase  which 
containing OPA (0.1%) and TEA (0.1%) was added 
for stability of the etoricoxib, that gives concentration 
of 100 µg/ml of ETOR and labeled as Standard stock 
ETOR.
2.8 Preparation of Calibration Curve for ETOR
2.9  Analysis  of  Arcoxia-60  (Sun  Pharmaceutical  
Ltd):  To  determine  the  content  of  ETOR  in 
conventional tablets (Label  claim 60 mg ETOR per 
tablet); the twenty tablets were weighed, their mean 
weight determined and they were finely powered and 
powder equivalent to 10.0mg ETOR was transferred 
into  a  100  ml  volumetric  flask  containing  ratio  of 
mobile phase, sonicated for 30 min and diluted to 100 
ml with mobile phase (10 µg/ml). OPA and TEA was 
added to avoid the degradation of the etoricoxib. The 
resulting solution was filtered,  using 0.22 µm filter 
(Millifilter,  Milford,  MA) and injected  into system. 
The  amount  of  ETOR  was  determined.  The  assay 
procedure was repeated for six times and calculated 
using following equation.
                Rt Cs
      Ct =    -----------
                    Rs
Where,  Ct  and  Cs  =  Concentration  of 
Sample and Standard Solution, respectively.
 Rt  and  Rs  =  Peak  Area  for  Sample  and 
Standard Solution, respectively. (9, 12, 13)
2.10 Validation of RP-HPLC Method
2.10.1  Accuracy:  Accuracy  of  the  method  was 
assessed  by  standard  addition  method  at  three 
different concentration levels i.e. 80%, 100%, 120%. 
From  sample  stock  solution  ETOR  (100  µg/ml), 
pipette  out  10 ml  to  each  of  four  different  100  ml 
volumetric flask and add to it  0.0 ml, 8 ml, 10 ml and 
12 ml of standard stock solution ETOR (100 µg/ml) 
and make up the volume with mobile phase. The % 
Recoveries  was  calculated  by  applying  regression 
equation.
2.10.2  Precision:  The  precision  of  an  analytical 
method was studied by performing repeatability and 
intermediate precision.
2.10.3 Repeatability:  Suitable aliquot from standard 
stock solution ETOR (100 µg/ml) 1 ml was pipetted 
in 10 ml volumetric flask and make up the volume to 
get final concentration of 10 µg/ml and analyzed six 
times  on  the  same  at  optimized  chromatographic 
conditions
2.10.4 Intermediate Precision
2.10.4.1 Intra-day Precision: Intra-day precision was 
determined  by  analyzing  the  standard  solutions  of 
ETOR (10, 11, 12 µg/ml) and at three different time 
intervals on same day.
2.10.4.2 Inter-day Precision: Inter-day precision was 
determined  by  analyzing  the  combined  standard 
solutions  of  ETOR  (10,  11,  12  µg/ml)  on  three 
consecutive days. The results were reported in terms 
of % RSD.
2.10.5  Linearity and  Range:  The  linearity  of 
analytical  method  for  ETOR  was  determined  by 
studying  standard  calibration  curves.  The  range  of 
analytical  method  was  decided  from  the  interval 
between upper and lower level of calibration curves 
by plotting the log curve.
2.10.6 Limit of Detection and Limit of Quantitation:  
Detection  limit  and  quantitation  limit  were 
determined  based  on  the  standard  deviation  of  y-
intercepts of six calibration curves and average slope 
of six calibration curves.
 LOD = 3.3 × Standard deviation of intercept
      Slope
 LOD = 10× Standard deviation of intercept
      Slope
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2.10.7 Robustness: Standard stock solution of ETOR 
(100 µg/ml)) were used and analyzed at different flow 
rate (0.9,  1.00,  1.1 ml/min) and at  different  mobile 
phase  ratio  (39:61:0.1:0.1,  40:60:0.1:0.1, 
41:59:0.1:0.1) separately.
2.10.8 System Suitability: Standard solution of ETOR 
(10  μg/ml)  was  prepared  and  analyzed. 
Chromatograms were studied for different parameters 
such as tailing factor, resolution and theoretical plates 
to  see  that  whether  they  comply  with  the 
recommended limit or not.
2.10.9  Specificity  and  Selectivity:  The  analytes 
should  have  no  interference  from  other  extraneous 
components  and  be  well  resolved  from  them. 
Specificity is a procedure to detect quantitatively the 
analyte  in  presence  of  component  that  may  be 
expected  to  be  present  in  the  sample  matrix,  while 
selectivity is the procedure to detect qualitatively the 
analyte  in  presence  of  components  that  may  be 
expected  to  be  present  in  the  sample  matrix.  The 
method  is  quite  selective.  There  was  no  other 
interfering peak around the retention time of ETOR; 
also the base line did not show any significant noise.
2.10.10 Ruggedness:  Ruggedness of the method was 
checked  by  two  different  analysts  keeping  same 
experimental  and  environmental  conditions.  An 
appropriate  concentration  10  μg/ml  of  ETOR  was 
subjected  to  analysis  and  concentration  was 
determined. This procedure was repeated six times. (4)
3. Results
3.1  Preliminary  analysis  of  drug:  Preliminary 
analysis of Etoricoxib such as description, solubility, 
identification test and assay were performed and was 
complied with BP. A white to slightly off-white fine 
powder  was  found  which  was  complied  with BP. 
Drug was  soluble  in  isopropyl  acetate,  ethanol  and 
toluene. Sparingly soluble in 2- propanol. Practically 
insoluble in water. Water content was found 0.2%.
3.2  High  Performance  liquid  Chromatographic  
Method
3.2.1.  Reverse  Phase  HPLC  method:  By  the 
literature survey  RP-HPLC method for estimation of 
Etoricoxib  was  reported  using  RP8 column 
(150mm×4.6mm  i.d.,  3.5μm  particle  size) column. 
Initially, RP8 column was tried to achieve good peak, 
but  it  was  not  giving  good  resolved  peak  and also 
giving a fronting of the peak, thus this prompted to 
use  Phenomenex  Gemini  C18  column  (250  mm  x 
4.6.0  mm,  5  µ),  thus  Phenomenex  Gemini  C18 
column  was  selected.  According  to  the  literature 
survey, mobile phase containing a mixture of water: 
ACN: OPA: TEA (40: 60: 0.1: 0.1) was used which 
showed good resolved  peak  at  a  flow rate 1ml/min 
and retention time was 2.7min with UV detection at 
245nm (Table 1, Figure 1, 2, 3).
Table 1 Observation and remarks of mobile phase 
Optimization of Chromatographic Conditions
Mobile Phase 
Composition
Inference Conclusion
Water: 
ACN:OPA:TEA 
(10 :90 :0.1 :
0.1,v/v/v/v)
Water: 
ACN:OPA:TEA 
(20 :80 :0.1 :
0.1,v/v/v/v)
Water: 
ACN:OPA:TEA
 (30 :70 :0.1 :
0.1,v/v/v/v)
Water: 
ACN:OPA:TEA
 (40 :60 :0.1 :
0.1,v/v/v/v)
Water: 
ACN:OPA:TEA 
(50 :50 :0.1 :
0.1,v/v/v/v)
Rt of ETOR 
greater
than 10
Rt of ETOR 
was
around 7.10
Rt of ETOR 
was
around 5
Rt of ETOR 
was
Around 2.7 ,
Assymmetry 
was
good
Asymmetry 
was
less
Mobile phase 
was
not satisfactory
Mobile phase 
was
not satisfactory
Mobile phase 
was
not satisfactory
Mobile phase 
was
Satisfactory 
(optimized)
Mobile phase 
was not
suitable
Figure 1 HPLC chromatogram of Blank (diluents) 
Water: ACN: OPA: TEA (40: 60: 0.1: 0.1, v/v/v/v)
Figure 2 HPLC chromatogram of ETOR standard 
(10 µg/ml) mobile phase at flow rate of 1 ml/min, 
at 245nm,
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Figure 3 HPLC chromatogram of sample ETOR 
(10 µg/ml) in the optimized mobile phase at flow 
rate of 1ml/min, at 245nm, C18 column
3.2.2  Selection  of  Analytical  Wavelength:  The 
standard  solutions  of  ETOR  (10  µg/ml)  in  mobile 
phase were scanned in the UV region of 200 - 400 nm 
and  the  overlain  spectra  were  recorded.  It  was 
observed that ETOR drugs showed the absorbance at 
245 nm. So,  the  wavelength  of  detection  used  was 
245 nm.
3.2.3 Linearity Study:  ETOR was found to be linear 
in the concentration range of 8-12 µg/ml, the results 
of which are given in Table 2, Table 3 and figure 4.
Table 2 Results of Calibration Curve of ETOR
S. 
No.
Concentration 
of ETOR 
[µg/ml]
Area 
Mean
% 
RSD
1 8 966.866 0.10
2 9 1094.57 0.11
3 10 1213.383 0.08
4 11 1328.304 0.07
5 12 1448.567 0.08
Table 3 Linear Regression Analysis of Calibration 
Curves for ETOR
Linearity Range (μg/ml) 8-12
Slope 119.71
Intercept 13.199
Correlation Coefficient (r2) 0.9997
LOD (μg/ml) 0.310
LOQ (μg/ml) 0.572
  
Figure 4 Calibration Curve of ETOR of RP-HPLC 
Method
3.2.4  Assay  of  Marketed  Formulation:  Amount  of 
ETOR present in the marketed formulation (Arcoxia-
60mg, Sun Pharmaceutical  Ltd.)  was found and the 
results are presented in Table 4.
Table 4 Assay Results of Arcoxia RP-HPLC 
Method
Amount 
present 
[μg/ml]
Amount found 
[μg/ml]
[%] of 
Assay
10 9.94 99.4
10 9.97 99.7
10 9.90 99.0
           
3.2.5 Validation Parameters
The developed method was validated in accordance to 
ICH guidelines.  Percentage  of  recoveries  of  ETOR 
was found  in  the  range  from  99.53 – 99.72%. 
Precision of the method was determined by % RSD 
found among intra-day precision, inter-day precision, 
repeatability. LOD and LOQ of ETOR were found to 
be 0.310 and 0.572µg/ml, respectively. For robustness 
study, the effect of change in of mobile phase, mobile 
phase ratio and flow rate (1.0 ± 0.2 ml/min) on the 
Mean peak area, % RSD and % Assay were studied. 
Standard solutions of ETOR (10 µg/ml), was prepared 
and analyzed at different  mobile phase ratio Water: 
ACN:OPA:TEA (10 :90 :0.1 :0.1, 20: 80: 0.1: 0.1, 30: 
70: 0.1: 0.1, 40: 60: 0.1: 0.1, 50: 50: 0.1: 0.1, v/v) and 
at  different  flow  rate  (0.99,  1.00,  1.1  ml/min). 
Percentage  RSD of  each  peak  in  all  variables  was 
found to be less than 3 % was mentioned in the Table 
5, 6, 7, 8, 9, 10.
Table 5 Results of Accuracy for RP-HPLC Method
Initial 
Amount 
 [ µg/ml] 
Amount 
added 
[µg/ml] 
Amt recovered
      ± S.D 
[µg/ml, n=3] 
% 
Recovery 
% 
RSD
10 8 17.97 ± 0.06 99.72 0.11
10 10 19.89 ± 0.05 99.53 0.10
10 12 21.87 ± 0.05 99.57 0.18
Table 6 Results of intra-day precision and inter-
day precision
Conc. 
[µg/ml]
Intra-day Precision Inter-day Precision
Mean % 
RSD 
[n= 3]
Mean % 
RSD 
[n= 3]
10 1213.383 0.08 1213.503 0.08
11 1328.304 0.07 1328.937 0.11
12 1448.437 0.08 1449.053 0.04
Table 7   Results of Repeatability Study for ETOR
Mean 1213.558
S.D 0.905
% RSD 0.075
Table 8 Result of Robustness Study: Variation in 
Mobile phase Ratio
Percentage Methanol 
in Mobile phase (v/v)
RT T
81 2.76 1.47
80 2.7 1.40
79 2.65 1.45
Mean ± SD 2.70±0.0550 1.44 ± 0.04
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Table 9 Results of Ruggedness
Analysts 
[n=3]
Amount found of ETOR 
[%]
% 
RSD
I 99.51 0.20
II 99.27 0.23
Table 10 Results of System Suitability Parameters
Analyte Retention 
time (min)
Tailing 
Factor
Theoretical 
plates (N)
Capacity 
Factor
ETOR 2.7 1.40 4122 0.92
4. Discussion
From  the  results  obtained,  chromatographic 
separation was achieved using a Phenomenex Gemini 
C18 column (250 mm x 4.6.0 mm, 5 µ) as a stationary 
phase was finalized; water, ACN, OPA, TEA in the 
ratio of 40:60:0.1:0.1 (v/v/v/v) as a mobile phase and 
retention time 2.7 min. This mobile phase is simple to 
prepare  and  economical.  From  the  optical 
characteristics of the proposed method it was found 
that  the  drug  obeys  linearity  range  within  the 
concentration of 8-12μg/ml. The results of precision 
study  showed  that  the  %RSD  was  less  than  2%, 
which  indicated  that  the  method  has  good 
reproducibility.  From the results shown in accuracy 
study, it was found that the % recovery values of pure 
drug from the preanalysed solutions of formulations 
were in between 99.53-99.72%, which indicated that 
the method is accurate. The sample recoveries in all 
formulations  were  in  good  agreement  with  their 
respective  label  claims  and  they  suggested  non-
interference  of  formulation  excipients  with  the 
analysis of drug in the proposed method. The system 
suitability parameters were within the specified limits. 
Hence the developed method was found to be simple, 
precise, accurate,  robust and rapid for determination 
of etoricoxib from pure drug and its dosage forms. 
5. Conclusion
RP-HPLC  was  found  to  more  precise,  accurate, 
rugged  and  robust  for  determination  of  Etoricoxib. 
The excipients usually present in the pharmaceutical 
formulation  did  not  interfere  with  determination  of 
Etoricoxib.  Developed  method  can  be  successfully 
used  in  laboratory  to  measure  the  concentration  of 
API  in  specific  dosage  form  .This  method  is  very 
beneficial  in  formulation  and  development 
department. This method is useful for identifying of 
analyte, purity testing, and assay. This is new concept 
for the validation of method development and method 
transfer in pharmaceutical companies. These methods 
are  very easy and less  time consuming compare  to 
other hectic methods and in these methods very less 
chemicals are used and also a less cost methods.
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